Navigation Links
FDA Panel Supports Anemia Drugs for Cancer Patients
Date:3/13/2008

But adds strong caveats on their use for some undergoing chemo

THURSDAY, March 13 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel voted Thursday to recommend continued use of blood-boosting drugs for cancer patients on chemotherapy, with the caveat that certain cancer sufferers should steer clear of the medications.

According to the Wall Street Journal, the panel voted 13-1 for letting Amgen Inc. continue selling Epogen and Aranesp and Johnson & Johnson continue selling Procrit. But the panel voted 11-2 to recommend against the drugs' use for cancer patients who are likely to be cured. And, in a 9-5 vote, the panel also recommended the drugs not be used in patients with breast or head and neck cancer.

FDA briefing documents filed this week before the meeting showed there are eight clinical trials that now suggest these widely used medications actually speed the growth of tumors and shorten the lives of cancer victims. Known as erythropoiesis-stimulating agents (ESAs), they work by stimulating red blood cell production.

"Whereas at the time of approval safety concerns were theoretical, there is now mounting evidence of documented effects on survival, tumor progression, and thrombotic events which require a re-assessment of the net benefits of this class of drugs," FDA officials stated. "Based on data provided to FDA, there is no evidence that ESAs improve quality of life or cancer outcomes."

Thursday's meeting is only the latest in a long string of FDA actions concerning the potential dangers of these drugs since their approval in the early 1990s.

This isn't the only group of patients using ESAs that concerns the FDA. In kidney patients, past research has found that if these drugs are used to raise hemoglobin levels above 12 grams per deciliter of blood, the risk of death increases.

The growing body of evidence led the FDA to have the drugs' manufactur
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Panel Weighs Safety of Anemia Drugs for Cancer Patients
2. Nasdaq Hearings Panel Grants TeamStaffs Request for Continued Listing Subject to a Reverse Stock Split
3. Is Cancer Community in Alignment About Cure and Costs? NCCN Conference Panel Asks
4. CDC Panel Urges Extending Flu Vaccine Coverage for Kids
5. Key Business, Labor and Academic Experts Join Stop Obesity Alliance Panel to Present Policy Perspectives and Recommendations to Reshape The Union
6. FDA Panel OKs 3 New Flu Strains for Next Years Vaccine
7. VA Creating Advisory Panel on Rural Health
8. Penn childhood obesity researchers panelists at AAAS Town Hall Event
9. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
10. Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses
11. Decongestant in OTC Cold Remedies Effective: FDA Panel
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Supports Anemia Drugs for Cancer Patients
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... EurekAlert! in 2010 was the discovery of a "golden ... finding put forth the new suggestion that matter on ... patterns as opposed to chaos. Stories on the ... EurekAlert! users in 2010. The most popular topics varied ...
... HealthDay Reporter , TUESDAY, March 22 (HealthDay News) -- ... reduce the risk of developing high blood pressure, a new ... risk of developing hypertension in those who consumed whole grain ... researcher Dr. Jinesh Kochar, of Beth Israel Deaconess Medical Center ...
... March 23 (HealthDay News) -- Reducing the workload of U.S. ... has not had a negative effect on patient safety and ... a new study contends. The findings, which stem from ... and United Kingdom, challenge concerns expressed by medical professionals that ...
... Chase, MD A recent study accepted for publication in The ... (JCEM) found that higher levels of perfluorocarbons (PFCs) in the ... in women between 42 and 64 years old. Women in ... significantly lower concentrations of estrogen when compared to women who ...
... of a young, apparently healthy athlete dying on the court or ... at Fennville High School, who died of cardiac arrest from an ... if enough is being done to identify athletes at risk for ... program to help prevent sudden cardiac death, but there is not ...
... In 1998, a study linking the measles, mumps and ... respected medical journal. For a decade, the study grabbed headlines ... and those with autistic children agonized that they allowed an ... was a fraud. The paper was retracted 12 years later, ...
Cached Medicine News:Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 3Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 4Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 5Health News:Whole Grain Cereal May Help Control Blood Pressure 2Health News:Whole Grain Cereal May Help Control Blood Pressure 3Health News:Exposure to chemicals in environment associated with onset of early menopause 2Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:Research practices must be changed to minimize fraud, deception 2
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... March 18, 2011 Mach 7 ... medical image management solutions, has collaborated with Massachusetts ... improve a highly specialized radiology department workflow scenario. ... Keystone Engine, MGH identified a use-case involving a ...
... Eagle®, the region,s leading food and fuel retailer, has ... Award. Giant Eagle is the second ever ... of individuals, corporations, institutions and organizations who have demonstrated ... impact in advancing the mission of the ADA. ...
Cached Medicine Technology:Massachusetts General Hospital Goes LIVE on Keystone Engine 2Massachusetts General Hospital Goes LIVE on Keystone Engine 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
... is the first and only ... 3 layers of the tear ... that lubricates and protects the ... helps seal in moisture and ...
...
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: